Generic : Meropenem
Thearapeutic : Antibiotics
Pack Size : 500 mg
Strength :
Dosage Form : Injection




  • Mepen 500 mg injection: Each vial contains sterile Meropenem 500 mg USP. Each ampoule contains 10 ml Water for Injection BP.
  • Mepen 1 gm injection:  Each vial contains sterile Meropenem 1 gm USP.  Each ampoule contains 10 ml Water for Injection BP.


Meropenem for injection is sterile, and pyrogen-free. synthetic, broad-spectrum, carbapenem antibiotic for intravenous administration. It penetrates bacterial cell walls with its high level of stability to all serine beta-lactamases and marked affinity for the Penicillin Binding Proteins (PBPs). The bactericidal activity of Meropenem results from the inhibition of cell wall synthesis. Meropenem exerts its action by interfering with the synthesis of vital cell wall components, which leads to cell death. Meropenem is relatively stable to human dehydropeptidase-1 (DHP-1) and therefore, does not require the addition of an inhibitor of DHP-1.


The in vitro antibacterial spectrum of Meropenem includes the majority of clinically significant Gram-positive and Gram-negative, aerobic and anaerobic strains of bacteria. Meropenem is indicated for treatment in adults and children of the following infections caused by single or multiple susceptible bacteria and as empiric therapy prior to the identification of the causative organisms: Lower Respiratory Tract Infections including cases of pneumonia and nosocomial pneumonia. Urinary Tract Infections including complicated infections, Intra-abdominal Infections, Gynaecological Infections including postpartum infections, endometritis and pelvic inflammatory disease. Skin and Skin Structure Infections, Meningitis, Septicaemia, Empiric treatment including initial monotherapy for presumed bacterial infections in host-compromised, neutropenic patients. Because of its broad spectrum of bactericidal activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria, Meropenem is effective for the treatment of polymicrobial infections.

Dosage and Administrations

A) Adults: The dosage and duration of therapy shall be established depending on the type and severity of infection and the condition of the patient. The recommended daily dosage is as follows: In the treatment of pneumonia, UTI. gynaecological infections such as endometritis, skin and skin structure infections- 500 mg IV every 8 hours. In the treatment of nosocomial pneumonia, peritonitis, presumed infections in neutropenic patients, and septicaemia- 1 gm IV every 8 hours. In cystic fibrosis- doses up to 2 gm every 8 hours. In meningitis- 2 gm every 8 hours.

Exceptions:1. Febrile episodes in neutropenic patients - the dose should be 1 gm every 8 hours. 2. Meningitis - the dose should be 2 gm every 8 hours. As with other antibiotics, caution may be required in using Meropenem as monotherapy in critically ill patients with known or suspected Pseudomonas aeruginosa lower respiratory tract infections. Regular sensitivity testing is recommended when treating Pseudomonas aeruginosa infections. Meropenem should be given as an intravenous bolus injection over approximately 5 minutes and 01 intravenous infusion over approximately 15 to 30 minutes.